INTRODUCTION {#rjz036s1}
============

Nineteen percent of patients newly diagnosed with colorectal cancer present with distant metastasis at the time of diagnosis and patients treated for cure develop metastatic disease in nearly 40%. Metastases from rectal cancer to multiple organs have been reported either as synchronous or metachronous lesions \[[@rjz036C1]\]. Regardless, metastatic disease from the rectum to unusual sites carries substantially poor prognosis.

CASE REPORT {#rjz036s2}
===========

A 43-year-old female, 10 weeks postpartum, underwent colonoscopy for bleeding per rectum showing a bulky tumour (Fig. [1](#rjz036F1){ref-type="fig"}) in the rectum at 5 cm. Histologically poorly differentiated adenocarcinoma of the rectum (Fig. [2](#rjz036F2){ref-type="fig"}) T3N1Mo. Underwent laparoscopic loop ileostomy formation for impending bowel obstruction. Bloods showed Hemoglobin13.6 g/dL, Bilirubin 10umol/L, CEA 3.6 ng/mL. MRI pelvis (Fig. [3](#rjz036F3){ref-type="fig"}a and [b](#rjz036F3){ref-type="fig"}) showed locally advanced annular neoplasm of mid and upper rectum. CT TAP (Fig. [4](#rjz036F4){ref-type="fig"}) reported no distant metastasis. She had neoadjuvant chemoradiothreapy with poor response. Post chemotherapy she noticed a lump in her right breast and axilla. Breast mammogram (Fig. [5](#rjz036F5){ref-type="fig"}a) showed 26 mm lesion in the right breast at 10 o\'clock position and ultrasound showed 27 mm lesion in right axilla. Core biopsy (Fig. [6](#rjz036F6){ref-type="fig"}) reported signet ring morphology. The tumour stained positive with CK20, CDX-2 and CEA. There was no staining with CK7, ER, PR or Her-2. The rectal biopsy specimen, also analysed for KRAS status, was KRAS/NRAS/BRAF negative. She is being followed up by oncology with FOLFOX+Panitumumab.

![Rectal cancer annular obstructing 5 cm from anal verge.](rjz036f01){#rjz036F1}

![Primary rectal biopsy showing mucinous poorly differentiated adenocarcinoma with signet cells KRAS/BRAS/NRAF negative.](rjz036f02){#rjz036F2}

![(**a**) MRI pelvis showing rectal tumour 7.3 cm two lymph nodes. (**b**) MRI pelvis Mucinous component within 5 mm of the right meso-rectum.](rjz036f03){#rjz036F3}

![Staging CT TAP showing no distant metastasis.](rjz036f04){#rjz036F4}

![(**a**) Mammogram post-neoadjuvant chemoradiothreapy showing right breast mass. (**b**) CT TAP pos-tneoadjuvant chemoradiothreapy showing enlarged right axillary lymph node.](rjz036f05){#rjz036F5}

![Breast core biopsy showing features similar to the primary rectal cancer.](rjz036f06){#rjz036F6}

DISCUSSION {#rjz036s3}
==========

Most breast metastases originate from the contra lateral breast \[[@rjz036C2]\]. Metastases to the breast from extra-mammary malignancies are rare 0.43%. Lymphoma, melanoma, sarcoma, lung carcinoma and ovarian tumour are common extra-mammary primary malignancies metastasizing to breast. Metastases from colon to breast was first reported by McIntosh and from rectum by Lal in 1999 \[[@rjz036C3]\]. A handful of cases of CRC metastasis to the breast have been reported, with two largest studies presenting two new cases each \[[@rjz036C4]\].

These metastatic lesions must be differentiated from primary breast tumours on the basis of history, clinical, radiological features, morphology of tumour and immune-histochemistry \[[@rjz036C5]\]. Most metastases present as palpable breast masses, occasionally adherent to the skin with slight left predominance, most common being upper outer quadrant. Rarely are there multiple or bilateral lesions \[[@rjz036C4]\]. Schaekelford *et al.* reported 55% to the left, 30% to the right and only 3% with bilateral breast metastasis. Toombs and Kalisher reported pain, tenderness or discharge is distinctly unusual. Nipple retraction has not been described, although adherence to the skin has been reported in 25%. Axillary node involvement was frequently encountered. Rumana, Rakesh Kumar, Ruiz, *et al.* \[[@rjz036C6], [@rjz036C7]\] reported cases of bilateral breast metastasis in young patients. Suganthi Krishnamurthy reported the youngest patient age 23 years old with rectal cancer metastasis to the breast. Hisham *et al*. \[[@rjz036C2]\] reported an unusual case of rectal carcinoma metastasis to the breast along with ocular involvement. Mihai *et al*. \[[@rjz036C8]\] reported a 53-year-old woman who post chemotherapy developed breast metastasis and later cutaneous metastasis similar in disease progression to our patient (Table [1](#rjz036TB1){ref-type="table"}). Table 1Few reported cases of rectal cancer metastasis to breast.ReferencesAgeSexPrimary cancerMetastasisLocation of breast metastasisRadiologyHistologyManagementOPDMy patient43FRectal cancerBreastRt upper quadrant/rt axillaMRI/CT TAP/Mammogram/USPoorly differentiated adenocarcinomaChemoradiothreapy,oncology follow-upOncologyLal and Joffe \[[@rjz036C3]\]69FRectal cancerT3N2R0MoBreast, liver, lung, brain, skinLeft upper outer quadrantCT TAP, FNA, wide local excision, elevated CEA, CA19.9Moderately differentiated mucin secreting adenocarcinoma breast histology moderately differentiated adenocarcinoma, ER negativeRadical anterior resectional wide local excision Poor response to chemotherapyRIP 4/12 after breast diagnosisSanchez *et al*. \[[@rjz036C1]\]36FRectal cancerBreast metastasisLeft outer upper quadrant 6 cm in sizeHisham *et al*. \[[@rjz036C2]\]32FRectal cancer10 months after APR, breast, spine, left eye, orbitLeft breast metastasisColonoscopy, CT abdomenpelvis Lumbosacral x-ray, MRI brainPoorly differentiated mucinous adenocarcinoma of the rectum, Breast Bx similarAPR and total mesorectal excision, excision of posterior vaginal wall, cuff of the tissue in the lateral pelvic wallRIP 2/12Mihai *et al*. \[[@rjz036C8]\]53FRectal cancerLung, breast metastasis, skin metastasisBreast lumpUltrasound, mammogram, FNA, core biopsies, local excisionChemothreapy, local excision, Post op chemothreapyRIPWakeham *et al*. \[[@rjz036C4]\]43FRectal CancerBilateral breastBreast lump 2×2.2 cm^2^Dukes C rectal cancerLi *et al*. \[[@rjz036C5]\]51FPerforated rectal cancerBreast, lung, soft tissue3 cm mass in the right upper quadrantCT abdomen pelvis,Mammogram,US breast,axillaInvasive poorly differentiated adenocarcinoma rectal carcinoma T4N0M0, Core Bx breast and axilla triple negative similar to rectal histologyLaparotomy colostomy, preop radichemothreapyRIP 12 monthsRumana Makhdomi \[[@rjz036C6]\]28FRectal cancer 4 cm away from anal vergeBilateral breast metastasisLargest 3×2 cm^2^ and smallest 2×1 cm^2^Sigmoidoscopy, colonoscopy, contrast enhanced computed tomography, mamamography, FNACMucus secreting adenocarcinoma with signet-ring differentiation, metastatic mucinous adenocarcinoma of the breast,ER/PR negativeAnteroperineal resection, adjuvant chemothreapyOPD follow upSingh *et al*. \[[@rjz036C10]\]42FRectal cancerT4 N1M0Right Breast lumpOuter upper quadrant 5×4 cm^2^Mammogram, FNAC, pleural fluid cytology, core needle biopsy, CEA mildly elevatedMucin secreting adenocarcinoma with signet ring cell Signet cell carcinoma CK20 positive, CK7, ER/PR negativeAnterior resection, chemoradiation, chemothreapyRIP 2/12 after breast metastasisHasukic *et al.* \[[@rjz036C9]\]63FRectal cancer T3N1M0Right breast mass 3×2 cmRight upper outer quadrantMammography, UltrasoundRectal adenocarcinoma T3N1M0, breast biopsy, Adenocarcinoma ER/PR negAPR, Adjuvant chemoradiothreapy, open excisional breast biopsyRIP post 4/12 breast pathologyRuiz *et al.* \[[@rjz036C7]\]36FRectal cancerBilateral breast left axilla right groinBilateral breastCT abdomen pelvis, Mammogram UltrasoundPoorly differentiated rectal carcinoma with signet ring cellT3N1M0APR with hysterectomy, adjuvant radiochemotherapy exploratory laparotomy, incisional bx of both breast, chemothreapy nine cyclesRIP 6 /12 after breast mets diagnosisTing Wang *et al.* \[11\]38MRectal cancerRight mammary mass 7 years after surgeryAnterior resection, core needle bx, neoadjuvant chemotherapy, modified radical mastectomySuganthi Krishnamurthy *et al.* \[12\]23FRectal cancerBreast/axillary metastasis two 1/2 months laterRight upper outer quadrantColonoscopy, CT TAP, FNAC, Core BxPoorly differentiated adenocarcinoma with signet cellEmergency laparotomy, loop colostomy, palliative chemotherapy

The time from initial diagnosis to metastasis to the breast varies between 1 month and 15 years, average between 1 and 5 years. Hasukic *et al.* \[[@rjz036C9]\] reported a 69 year old patient who had breast metastasis 30 months after the APR. Ting Wang *et al.* reported a 38 year old male who underwent anterior resection developing breast metastasis after 7 years.

Differentiating primary from metastatic breast neoplasms is not always easy. Mammograms help in settling doubts. The classic mammographic finding is a rounded, well-circumscribed mass no speculation, microcalcification or thickening of the skin \[[@rjz036C1], [@rjz036C4]\]. Typical ultrasound (US) features of haematogenous metastases include single or multiple, round to oval shaped, well-circumscribed hypo-echoic masses without spiculations, calcifications, or architectural distortion located superficially in subcutaneous tissue or immediately adjacent to the breast parenchyma.

Histologically, the metastatic tumours show the morphological characteristics of the primary tumours. Excisional or incisional biopsy is the most commonly used procedure for the differential diagnosis \[[@rjz036C10]\]. There is increasing use of needle core biopsy rather than fine needle aspiration cytology. Silverman in his study reported 2529 FNA breast biopsies, 666 were malignant, only 18 of these were from extra-mammary malignancies. Alvardo *et al.* in his series of 10 650 breast biopsies in Mexican population, reported 24 extra-mammary cases.

In majority cases, immune-histochemistry can help to make an accurate diagnosis. Testing for expression of CK7 and CK20 is considered to be most beneficial. The great majority of primary breast cancers are CK7-positive and CK20-negative, while colorectal carcinomas are usually CK7-negative and CK20-positive. Mucinous differentiation of colorectal cancer is associated with poor outcome. In our patient, rectal tumour showed mucinous differentiation with features of signet ring cell subtype which explains the poor response to the neoadjuvant chemotherapy.

Most patients succumb to the aggressive course of the disease within a year after the diagnosis of the primary tumour. Surgical treatment of secondary breast cancer is usually palliative. Mastectomy has no significant role, systemic chemotherapy is necessary in these patients. Metastasectomy with effective systemic chemotherapy can prolong survival of these patients \[[@rjz036C1], [@rjz036C4]\]. However, its role is mostly palliative.

Treatment options for patients with metastatic colorectal cancer (mCRC) have changed considerably with the introduction of antiepidermal growth factor receptor (EGFR) therapies targeting EGFR transduction cascade. KRAS genotyping is mandatory in mCRC treatment prior to undertaking (EGFR) monoclonal antibody therapy. KRAS mutations have been identified as a reliably strong negative predictive factor to anti-EGFR monoclonal antibody therapies in mCRC patients.

In conclusion, a new breast mass in a patient with a known primary rectal tumour has to be considered as a breast metastasis until proven otherwise despite its rare occurrence!
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